Author:
Paterson S C,Smith K D,Holyoake T L,Jørgensen H G
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Barthe C, Cony-Makhoul P, Melo J, Mahon J (2001) Roots of clinical resistance to STI-571 cancer therapy. Science 293: 2163
2. Blain PG, Mucklow JC, Rawlins MD, Roberts DF, Routledge PA, Shand DG (1985) Determinants of plasma alpha-1-acid glycoprotein (AAG) concentrations in health. Br J Clin Pharmacol 20: 500–502
3. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, Herrmann R, Lynch K, Hughes T (2002) High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99: 3472–3475
4. Brinkmann U, Roots I, Eichelbaum M (2001) Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. Drug Discov Today 6: 835–839
5. Deininger M, Leiblein S, Keohler T, Guenther R, Kovacs I, Ben-Am M, Al-Ali H, Reiner K, Niederwieser D (2001) In vivo resistance to Glivec is not consistantly associated with resistance in vitro but may be related to increased MDR-1 expression. Blood 98: 176b
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献